SCHEMBL29585835

SCHEMBL29585835

C[C@H](c1ccc(Cl)c(Cl)c1)N1CCCCC1

nearest known ligand 0.56

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
SLC6A3 Q01959 8/20 0.56
SLC6A2 P23975 7/20 0.56
SLC6A4 P31645 6/20 0.56
PTGS1 P23219 1/20 0.46
OGA O60502 1/20 0.45
SMN1; SMN2 Q16637 2/20 0.45
MEN1 O00255 1/20 0.45
ALDH1A1 P00352 1/20 0.45
GAA P10253 1/20 0.45
ADAM17 P78536 1/20 0.45
KMT2A Q03164 1/20 0.45
MCL1 Q07820 1/20 0.45
ACHE P22303 1/20 0.43
POLB P06746 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29585404 1.00 SLC6A3 (0.56) SLC6A3SLC6A2SLC6A4PTGS1OGA
SCHEMBL22206745 1.00 SLC6A3 (0.56) SLC6A3SLC6A2SLC6A4PTGS1OGA
SCHEMBL22206766 1.00 SLC6A3 (0.56) SLC6A3SLC6A2SLC6A4PTGS1OGA
SCHEMBL31669101 0.98 SLC6A3 (0.55) SLC6A3SLC6A2SLC6A4PTGS1OGA
SCHEMBL6447344 0.86 SLC6A3 (0.48) SLC6A3SLC6A2SLC6A4PTGS1SMN1; SMN2
SCHEMBL5554008 0.86 SLC6A3 (0.48) SLC6A3SLC6A2SLC6A4PTGS1SMN1; SMN2
SCHEMBL3704355 0.83 PTGS1 (0.50) SLC6A3SLC6A2SLC6A4PTGS1OGA
SCHEMBL22206767 0.79 CHRM2 (0.57) SLC6A3SLC6A2SLC6A4SMN1; SMN2MEN1
SCHEMBL22206739 0.79 CHRM2 (0.57) SLC6A3SLC6A2SLC6A4SMN1; SMN2MEN1
SCHEMBL7312748 0.78 SLC6A2 (0.68) SLC6A3SLC6A2SLC6A4SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2024-05-16 US disclosed
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof AMGEN INC. (US) 2023-10-10 US disclosed
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF AMGEN INC. 2022-09-08 US disclosed
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof CYTOKINETICS, INC. (US) 2022-04-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11780826-B2 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 SLC6A3 4306/4885SLC6A2 1343/4885SLC6A4 2425/4885
US-20240158372-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 SLC6A3 4306/4885SLC6A2 1343/4885SLC6A4 2425/4885
US-20220281850-A1 BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF TNNI3, TNNT2, TNNC1 SLC6A3 4306/4885SLC6A2 1343/4885SLC6A4 2425/4885
US-11299479-B1 Bisamide sarcomere activating compounds and uses thereof TNNI3, TNNT2, TNNC1 SLC6A3 4306/4885SLC6A2 1343/4885SLC6A4 2425/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.